Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. (Q38455680)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yoo Hong Min

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yeung-Chul Mun

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Yun-Gyoo Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Inho Kim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sung-Soo Yoon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Seonyang Park

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jeong-Ok Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Soo-Mee Bang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hyeon Gyu Yi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Chul Soo Kim

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yong Park

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Byung-Soo Kim

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Chu-Myoung Seong

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jinny Park

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jae Hoon Lee

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sung-Yong Kim

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hong Ghi Lee

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yeo-Kyeoung Kim

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hyeoung-Joon Kim

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Korean Society of Haematology AML/MDS working party

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

21 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

339-347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

Proposals for the classification of the myelodysplastic syndromes

24 February 2020

cites work

1 reference

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

21 January 2018

1 reference

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis

21 January 2018

1 reference

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

21 January 2018

1 reference

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis

21 January 2018

1 reference

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

21 January 2018

1 reference

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

Myelodysplastic Syndromes

21 January 2018

1 reference

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12256

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23432512%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference